neovascular age-related macular degeneration

Topical squalamine offers novel, promising therapy for nAMD
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Real-world outcomes with aflibercept better in treatment-naïve patientsAfter 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.
DARPin molecule prolongs anti-VEGF activity in nAMDA phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.
Algorithm could change way to treat wet AMDAn algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
Treat-and-extend may lead to better AMD resultsTreating neovascular age-related macular degeneration (nAMD) patients with anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis, Genentech) on a monthly regimen has produced “great results” in clinical trials, said Prof. Mark C. Gillies, MBBS, PhD. “But what happens after that and what happens in real world practice?”
‘Ideal’ disease control leads to better nAMD outcomesNeovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Long-term aflibercept effective for nAMD after other anti-VEGF therapies failedAflibercept (Eylea, Regeneron Pharmaceuticals) intravitreal injection, administered according to an as-needed regimen, improved the anatomic outcomes in many eyes refractory to monthly bevacizumab or ranibizumab injections that had persistent or recurrent fluid. However, half of the patients might require aflibercept injections every 4 weeks in order to achieve a completely dry retina.
Google DeepMind searches for signs of retinopathyGoogle is using its DeepMind computing system to search for early signs of diabetic retinopathy and neovascular age-related macular degeneration (nAMD), the company announced this month.
Advancing diagnostics and detection of neovascular age-related macular degenerationEarly detection and treatment is essential to preserve vision in patients with age-related macular degeneration. A new device, the ForeseeHome®, uses preferential hyperacuity perimetry for early detection of choroidal neovascularisation before symptoms develop.